Original scientific paper

https://doi.org/10.21860/medflum2021_365323

Hybrid SPECT/CT Somatostatin Receptor Imaging of Neuroendocrine Tumours

Matej Maršić orcid.org/0000-0002-5965-8603 ; Klinika za otorinolaringologiju i kirurgiju glave i vrata, KBC Rijeka, Rijeka, Hrvatska
Tihana Klarica Gembić orcid.org/0000-0001-7209-6820 ; Klinički zavod za nuklearnu medicinu, KBC Rijeka, Rijeka, Hrvatska
Neva Girotto orcid.org/0000-0001-5445-3310 ; Klinički zavod za nuklearnu medicinu, KBC Rijeka, Rijeka, Hrvatska, Medicinski fakultet Sveučilišta u Rijeci, Rijeka, Hrvatska
Ivan Pribanić orcid.org/0000-0002-8261-8394 ; Zavod za medicinsku fiziku i zaštitu od zračenja KBC Rijeka, Rijeka, Hrvatska, Medicinski fakultet Sveučilišta u Rijeci, Rijeka, Hrvatska
Tatjana Bogović Crnčić orcid.org/0000-0003-4152-7928 ; Klinički zavod za nuklearnu medicinu, KBC Rijeka, Rijeka, Hrvatska, Medicinski fakultet Sveučilišta u Rijeci, Rijeka, Hrvatska
Svjetlana Grbac-Ivanković orcid.org/0000-0002-4958-6183 ; Klinički zavod za nuklearnu medicinu, KBC Rijeka, Rijeka, Hrvatska, Medicinski fakultet Sveučilišta u Rijeci, Rijeka, Hrvatska

Abstract

The aim: The aim of this study was to evaluate the significance of somatostatin receptor single-photon emission computed tomography/computed tomography (SR SPECT/CT) with 99mTc-EDDA/HYNIC-Tyr3-octreotide (99mTc-Tektrotyd) in diagnostics and staging of patients with neuroendocrine tumours. Patients and methods: We retrospectively enrolled 120 patients with histologically proven NET who underwent SR SPECT/CT between January 2013 and February 2017. The patients’ data and SR SPECT/CT findings regarding primary lesion and metastases were analysed. In 45 patients, 2-deoxy-2-18F-fluoroglucose positron emission computed tomography/computed tomography (18F-FDG PET/CT) was performed, and the findings were compared to SR SPECT/CT and chromogranin A values. Results: Out of 120 patients, 47 (39%) underwent SR SPECT/CT after surgical removal of the primary lesion. In 73 (61%) remaining patients, the primary lesion was detected on SR SPECT/CT in 56 (77%), in 9 (12%) lesion did not accumulate 99mTc-Tektrotyd. SR SPECT/CT was negative in the remaining 8 (11%) patients with unknown primary. Out of 68 patients (57%) with metastases, 57 (84%) were detected on SR SPECT/CT, while 11 did not accumulate 99mTc- Tektrotyd. 18F-FDG PET/CT was performed in 45 patients, and findings were concordant with SR SPECT/CT in 27 (60%). The the sensitivity of SR SPECT/CT was 77% for primary lesions and 84% for metastases, and sensitivity of 18F-FDG PET/CT was 75% 76%, respectively. In 70 (58%) patients with available chromogranin A no statistically significant correlation was found with imaging methods. Conclusion: In patients with NET and negative SR SPECT/CT findings, 18F-FDG PET/CT should be recommended and vice versa, because of the complementarity of these procedures.

Keywords

neuroendocrine tumours; somatostatin receptor; 99mTc-EDDA/HYNIC-Tyr3-octreotid; SPECT/CT; 18F-FDG PET/CT

Hrčak ID:

251264

URI

https://hrcak.srce.hr/251264

Publication date:

1.3.2021.

Article data in other languages: croatian

Visits: 2.972 *